Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib effects on cardiac function in rheumatoid arthritis
NL-OMON59537Phase 4Completed
- Sponsor
- Reade
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of filgotinib in rheumatoid arthritis (RA) (2 cohorts), sponsored by Reade. Primary endpoint: Change in left ventricular function after 1 year of filgotinib. Started Jul 2025; status: completed.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON59537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59537.